[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.82.105. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Case Report/Case Series
October 2014

Symptomatic Hepatocellular Liver Injury With Hyperbilirubinemia in Two Patients Treated With Rivaroxaban

Author Affiliations
  • 1Department of Clinical Pharmacology and Toxicology, University Hospital Basel, Basel, Switzerland
  • 2Regional Pharmacovigilance Center, University Hospital Basel, Basel, Switzerland
  • 3Institute of Pathology, University of Basel, Basel, Switzerland
  • 4Department of Hepatology and Gastroenterology, University Hospital Basel, Basel, Switzerland
JAMA Intern Med. 2014;174(10):1683-1686. doi:10.1001/jamainternmed.2014.3912
Abstract

Importance  Treatment with the new oral anticoagulant rivaroxaban can be associated with severe liver injury.

Observations  We report 2 patients with predominantly hepatocellular liver injury that had onset during treatment with rivaroxaban. Both were symptomatic, had massively elevated transaminase activity levels and hyperbilirubinemia, and fulfilled the criteria of Hy’s law. Liver biopsy in 1 patient revealed centroacinar hepatocyte necrosis as the predominant finding. Both patients showed a rapid biochemical and clinical recovery after discontinuing rivaroxaban therapy. Between 2008 and 2013, 42 cases of liver injury possibly associated with rivaroxaban treatment have been reported to the Swiss Agency of Therapeutic Products (Swissmedic). Thirteen of these patients fulfilled the criteria of Hy’s law.

Conclusions and Relevance  Treatment with rivaroxaban can be associated with severe, symptomatic liver injury. Physicians should be aware of this adverse drug reaction. We propose rapid discontinuation of treatment with rivaroxaban in case of symptomatic liver injury and, taking into account its severity, avoiding reexposure.

Introduction

Rivaroxaban is a selective, competitive, active site–directed factor Xa inhibitor1 that is currently approved in many countries for the prevention of systemic embolism in patients with nonvalvular atrial fibrillation, prevention of deep vein thrombosis after orthopedic surgery, and for the treatment of deep vein thrombosis and/or pulmonary embolism.2 In some countries, rivaroxaban has also been approved for the prevention of atherothrombotic events in patients with acute coronary syndrome. Based on predictable pharmacokinetics and pharmacodynamics, a fixed dose of rivaroxaban is usually administered once daily without routine coagulation testing. Approximately one-third of the orally administered drug is eliminated unchanged by the kidney, and the rest is metabolized in the liver and eliminated via bile or urine.2,3 Hepatic metabolism of rivaroxaban is mainly by cytochrome P450 (CYP) 3A4, facilitating interactions with CYP3A4 inhibitors or CYP inducers.2,3

The most common adverse effects of rivaroxaban use are hemorrhages observed mostly in the gastrointestinal tract, whereas cerebral or spinal hemorrhages are rarer.4,5 Other adverse effects include mainly skin reactions and liver injury. In an analysis of the 4 RECORD (Regulation of Coagulation in Major Orthopedic Surgery Reducing the Risk of Deep Venous Thrombosis and Pulmonary Embolism) studies including patients who had undergone orthopedic surgery, 2.33% of the 6183 patients treated with rivaroxaban had transaminase levels more than 3 times the upper limit of normal (ULN).6 Symptomatic liver injury has recently been reported in a series of 14 patients treated with rivaroxaban.7 We report 2 additional patients treated with rivaroxaban with symptomatic liver injury who fulfilled the criteria of Hy’s law.8

Report of Cases

The first patient was a 52-year-old man who developed liver injury 2 months after starting therapy with rivaroxaban (Table). Rivaroxaban (10 mg per day) was used for the prevention of deep vein thrombosis after internal fixation of a tibia fracture. Two months after starting treatment with rivaroxaban, the patient presented with loss of appetite, nausea, and jaundice. Viral hepatitis was excluded serologically, the patient had no history of alcohol or drug abuse, and hemodynamic liver injury was excluded by a Doppler ultrasound that had normal results. Analysis of a blood sample revealed a massive elevation of serum alanine aminotransferase concentration (1740 U/L [ULN, 59 U/L; to convert to microkatals per liter, multiply by 0.0167]) and a slight elevation of alkaline phosphatase concentration (136 U/L [ULN, 129 U/L; to convert to microkatals per liter, multiply by 0.0167]) (Figure 1 and Table), compatible with hepatocellular liver injury.9 As expected from the clinical presentation, the serum bilirubin concentration was elevated (18.7 mg/dL [ULN, 1.5 mg/dL]; to convert to micromoles per liter, multiply by 17.104). All drug treatment (pantoprazole sodium, dipyrone, ibuprofen lysine, and rivaroxaban) was discontinued on the first day of hospitalization. During hospitalization, a liver biopsy was obtained, which revealed severe lobular hepatitis with perivenular confluent necrosis (Figure 2) and no other pathological features. The lobular architecture was preserved, and fibrosis of portal tracts was not present. These histological findings were judged to be well compatible with drug-related liver injury. Signs and symptoms of liver injury reversed rapidly after cessation of rivaroxaban treatment; the patient had a full clinical and partial biochemical recovery after 14 days. The patient was not reexposed to rivaroxaban or the other drugs with which he had been treated. Taking into account the fact that the patient had been treated with other potentially hepatotoxic drugs (see Discussion), the causality assessment was “possible.”10

Table.  
Patient Characteristics Including Concomitant Medication
Patient Characteristics Including Concomitant Medication
Figure 1.
Clinical Course of Patient 1
Clinical Course of Patient 1

The patient was hospitalized on day 0, and rivaroxaban therapy was discontinued. A liver biopsy was obtained on day 3. On day 19, the patient had made a full clinical recovery. At this time, the activities of alkaline phosphatase and aspartate aminotransferase (not shown) had normalized, whereas the activity of alanine aminotransferase and the serum bilirubin concentration were still slightly elevated.

Figure 2.
Liver Biopsy of Patient 1
Liver Biopsy of Patient 1

A, At low magnification, the lobular architecture is preserved and a minimal lymphocytic inflammation of portal tracts and perivenular confluent bridging necrosis are detectable (hematoxylin-eosin, original magnification ×100). B, At higher magnification, perivenular confluent necrosis with cell dropout, mild mononuclear inflammation, and several macrophages containing ceroid pigment can be detected (hematoxylin-eosin, original magnification ×200).

The second patient was a 73-year-old woman who had received a total knee replacement and was treated with rivaroxaban (10 mg per day) for the prevention of deep vein thrombosis. Four weeks after starting rivaroxaban treatment, she developed jaundice and pruritus and required hospitalization (Table). The diagnostic tests revealed mixed liver injury (aspartate aminotransferase level, 139 U/L [ULN, 34 U/L; to convert to microkatals per liter, multiply by 0.0167]; alanine aminotransferase level, 334 U/L [ULN, 41 U/L]; gamma-glutamyl transpeptidase level, 566 U/L [ULN, 40 U/L; to convert to microkatals per liter, multiply by 0.0167]; alkaline phosphatase level, 363 U/L [ULN, 104 U/L])9 and hyperbilirubinemia (serum bilirubin concentration, 7.54 mg/dL [ULN, 1.1 mg/dL]). Rivaroxaban therapy was discontinued on the day of hospitalization, whereas treatment with levothyroxine sodium and lisinopril was continued. Viral hepatitis was excluded serologically, screening for autoimmune liver disease had negative results, a Doppler ultrasound of the liver had normal results, and the patient had no history of alcohol or drug abuse. A liver biopsy was not obtained in this patient. Liver enzyme levels and bilirubin concentration resolved completely within 2 weeks after rivaroxaban treatment had been withdrawn. The patient was not reexposed to rivaroxaban. The causality assessment in this patient was “probable.”10

Discussion

Drug-induced liver injury (DILI) is one of the most common drug-related adverse reactions and can result in acute liver failure, which may necessitate emergency liver transplantation or end fatally. The diagnosis of DILI is challenging because the liver histological analysis may not be diagnostic, specific biomarkers are lacking, and there are multiple additional factors such as treatment with other drugs or concomitant liver diseases that can produce similar clinical, laboratory, and/or histological features.11

The assessment of suspected DILI cases consists therefore of 2 major diagnostic processes: the exclusion of other causes of liver injury and the identification of a pattern of disease manifestations that is temporally related to exposure to the suspected drug.12 In the present cases, other diseases such as viral hepatitis, exposure to alcohol or other toxins, autoimmune hepatitis, and hemodynamic liver injury have been excluded and there were no direct (case 1) or indirect markers of liver cirrhosis. The clinical pattern of liver injury was quite similar in the 2 patients: both experienced nausea and loss of appetite, were jaundiced, and showed a rapid improvement after rivaroxaban therapy was discontinued. Massive elevations of serum transaminase activities and bilirubin concentrations were the predominant laboratory findings, whereas alkaline phosphatase level was elevated only slightly. The results of the liver biopsy in patient 1, showing perivenular hepatocyte necrosis as the key finding, were compatible with the predominant hepatocellular pattern of the clinical presentation.

Besides clinical pattern and liver biopsy findings, the rapid clinical and biochemical response after discontinuation of rivaroxaban treatment is also compatible with drug-associated liver injury. Both patients had already started to improve 1 day after discontinuing rivaroxaban treatment and eventually recovered over the next 2 weeks. Because rivaroxaban has a half-life in the range of 10 hours,2 a rapid improvement of liver injury could be expected on the assumption that the toxic effects are related to the presence of rivaroxaban or a metabolite with a short half-life.

The causality rating was “possible” for case 1 and “probable” for case 2.10 In case 1, also ibuprofen13 and, less likely, pantoprazole14 could have caused liver injury, whereas liver injury has so far not been reported for dipyrone. In case 2, only treatment with rivaroxaban but not the other drugs (levothyroxine and lisinopril) was discontinued. Taking into account the similarity of the clinical presentation of the 2 patients, we consider treatment with rivaroxaban the most likely cause of liver injury in both patients.

The present report is not suited to provide a mechanism for the hepatotoxicity of rivaroxaban. Because immunological features were absent in the liver biopsy of patient 1, as well as in the clinical presentation of both patients, metabolic toxic effects of rivaroxaban and/or of a rivaroxaban metabolite are a more likely possibility. The perivenular localization of liver damage is compatible with the formation of toxic metabolites because CYP3A4, the most important CYP for rivaroxaban metabolism,2,3 has a centroacinar localization in adults.15

Between 2008 and 2013, 42 cases of suspected adverse drug reactions (including the 2 cases described herein) of the organ class “liver and biliary system disorders” (according to the World Health Organization’s adverse reaction terminology) associated with rivaroxaban have been submitted to the Pharmacovigilance Unit of the Swiss Agency of Therapeutic Products (Swissmedic). The reporting rate of liver injury associated with rivaroxaban in Switzerland increased during the past 2 years, probably primarily reflecting increased prescription rates. Per reported case, a mean of 2.6 suspected drugs (median [range], 1 [1-11]) and a mean of 1.4 liver events were coded, including jaundice in 14 and liver failure in 1 of them. Thirteen cases (our 2 cases included) showed a pattern of liver injury similar to that of the 2 cases described by us with alanine aminotransferase level greater than 3 times ULN and serum bilirubin concentration greater than 2 times ULN, fulfilling the principles of Hy’s law.8

One of the 6 Swiss Regional Pharmacovigilance Centers recently published a series of 14 cases of rivaroxaban-induced DILI reported to that center (included in the 42 Swiss reports).7 Similar to our 2 cases, 10 of the 14 patients had alanine aminotransferase values greater than 5 times ULN; 9, serum bilirubin concentrations greater than 2 times ULN; most of them were symptomatic; and 13 patients recovered after discontinuing rivaroxaban treatment. The similarity in the clinical presentation of the patients reported by us and by Russmann et al7 strengthens the conclusion that rivaroxaban was causing liver injury in these patients.

Conclusions

Treatment with rivaroxaban can be associated with severe hepatocellular liver injury, with some patients fulfilling the criteria of Hy’s law. After discontinuation of rivaroxaban therapy, affected patients show a rapid clinical and biochemical improvement, eventually resulting in complete recovery. Physicians should be aware of this potentially severe adverse drug reaction and should inform patients about possible symptoms when prescribing the drug. We propose rapid discontinuation of treatment with rivaroxaban in case of symptomatic liver injury and, considering the possible severity of liver injury, avoiding reexposure. A warning about symptomatic liver injury should be included in the drug labels.

Back to top
Article Information

Accepted for Publication: June 2, 2014.

Corresponding Author: Stephan Krähenbühl, MD, PhD, Clinical Pharmacology & Toxicology, University Hospital, 4031 Basel, Switzerland (kraehenbuehl@uhbs.ch).

Published Online: August 25, 2014. doi:10.1001/jamainternmed.2014.3912.

Author Contributions: Dr Krähenbühl had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Rätz Bravo, Heim, Krähenbühl.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: Liakoni, Rätz Bravo, Krähenbühl.

Critical revision of the manuscript for important intellectual content: Rätz Bravo, Terracciano, Heim, Krähenbühl.

Obtained funding: Heim, Krähenbühl.

Administrative, technical, or material support: Liakoni, Rätz Bravo.

Study supervision: Terracciano, Heim, Krähenbühl.

Conflict of Interest Disclosures: None reported.

References
1.
Perzborn  E, Roehrig  S, Straub  A, Kubitza  D, Misselwitz  F.  The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor. Nat Rev Drug Discov. 2011;10(1):61-75.
PubMedArticle
2.
Harder  S, Graff  J.  Novel oral anticoagulants: clinical pharmacology, indications and practical considerations. Eur J Clin Pharmacol. 2013;69(9):1617-1633.
PubMedArticle
3.
Gong  IY, Kim  RB.  Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban. Can J Cardiol. 2013;29(7)(suppl):S24-S33.
PubMedArticle
4.
Bondarenko  M, Curti  C, Montana  M, Rathelot  P, Vanelle  P.  Efficacy and toxicity of factor Xa inhibitors. J Pharm Pharm Sci. 2013;16(1):74-88.
PubMed
5.
Ufer  M.  Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development. Thromb Haemost. 2010;103(3):572-585.
PubMedArticle
6.
Watkins  PB, Desai  M, Berkowitz  SD,  et al.  Evaluation of drug-induced serious hepatotoxicity (eDISH): application of this data organization approach to phase III clinical trials of rivaroxaban after total hip or knee replacement surgery. Drug Saf. 2011;34(3):243-252.
PubMedArticle
7.
Russmann  S, Niedrig  DF, Budmiger  M,  et al.  Rivaroxaban postmarketing risk of liver injury. J Hepatol. 2014;61(2):293-300.Article
8.
Björnsson  E.  Drug-induced liver injury: Hy’s rule revisited. Clin Pharmacol Ther. 2006;79(6):521-528.
PubMedArticle
9.
Bénichou  C.  Criteria of drug-induced liver disorders: report of an international consensus meeting. J Hepatol. 1990;11(2):272-276.
PubMedArticle
10.
Edwards  IR, Aronson  JK.  Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356(9237):1255-1259.
PubMedArticle
11.
Navarro  VJ, Senior  JR.  Drug-related hepatotoxicity. N Engl J Med. 2006;354(7):731-739.
PubMedArticle
12.
Suzuki  A, Andrade  RJ, Bjornsson  E,  et al.  Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in VigiBase: unified list based on international collaborative work. Drug Saf. 2010;33(6):503-522.
PubMedArticle
13.
Gulmez  SE, Larrey  D, Pageaux  GP,  et al.  Transplantation for acute liver failure in patients exposed to NSAIDs or paracetamol (acetaminophen): the multinational case-population SALT study. Drug Saf. 2013;36(2):135-144.
PubMedArticle
14.
Cordes  A, Vogt  W, Maier  KP.  Pantoprazole-induced hepatitis [in German]. Dtsch Med Wochenschr. 2003;128(12):611-614.
PubMedArticle
15.
Ratanasavanh  D, Beaune  P, Morel  F, Flinois  JP, Guengerich  FP, Guillouzo  A.  Intralobular distribution and quantitation of cytochrome P-450 enzymes in human liver as a function of age. Hepatology. 1991;13(6):1142-1151.
PubMedArticle
×